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Abstract
Fenofibrate changed the expression of chemokine genes in circulating leukocytes of HIV-infected
patients with hypertriglyceridemia. The data suggest that fenofibrate when effective in the
treatment of lipoprotein abnormalities, may act as a modulator of systemic inflammation. This
particular action, therefore, may also influence the clinical course of the disease.
Background
The impact of mutant chemokine ligands and receptors in
the host susceptibility to HIV infection, in the clinical
course of the disease and in the development of new ther-
apies has been extensively described [1]. Chemokines
have also been implicated in the higher rates of athero-
sclerosis observed in HIV-infected patients which has
been partially attributed to either a direct effect of highly
active antiretroviral therapies or the concomitant meta-
bolic abnormalities [2-4]. Treatment of HIV infection,
particularly with the use of protease inhibitors (PIs), can
raise triglyceride levels to the threshold indicated for inter-
vention. Therefore, the need to maintain viral suppression
may be challenged by the need to treat abnormal lipid lev-
els. Fibrates, ligands for peroxisome proliferator-activated
receptor α (PPARα), represent an effective treatment for
hypertriglyceridemia that reduce coronary events and
delay progression of coronary atherosclerosis [5,6]. We
hypothesized that such a treatment with fenofibrate may
change the expression of chemokine genes in tissues and
that this effect could be readily observed in circulating leu-
kocytes.
Methods
Patients included in this cross-sectional study are partici-
pants of a previous study and the design has been already
described [3]. Participants were selected among those on
a PIs regimen and undetectable viral load during the pre-
vious 12 months. They were free of liver and renal disease.
Forty-three patients were considered normotriglyceri-
demic and 39 hypertriglyceridemics (plasma values below
or above the accepted threshold of 1.69 mmol/L). Fifteen
of these hypertriglyceridemic patients were being treated
with fenofibrate (160 mg/day) for at least six month, after
having fulfilled the eligibility criteria (more than 6
months on stable HAART, more than 18 years of age, and
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a fasting triglyceride concentration >1.69 mmol/L). We
collated pertinent HIV-related clinical and laboratory data
as well as data on the course of plasma lipid profile from
their clinical notes. Three mL of blood were collected into
TEMPUS blood RNA tubes (ABI, Foster City, CA, USA)
from which total RNA was isolated using the ABI PRISM
6100 (Applied Biosystems, Foster City, USA). TaqMan
primers and probes were obtained from validated Assays-
on-Demand products (Applied Biosystems) (Figure 1) to
be used in a Micro Fluidic Card on the 7900HT Real Time
(A) Effect of treatment with fenofibrate (160 mg/day) in HIV-infected patients with hypertriglyceridemia (treated HTG, n = 15)  with respect to untreated normolipemics (NL, n = 43) and hypertriglyceridemics (untreated HTG, n = 24) subjects Figure 1
(A) Effect of treatment with fenofibrate (160 mg/day) in HIV-infected patients with hypertriglyceridemia 
(treated HTG, n = 15) with respect to untreated normolipemics (NL, n = 43) and hypertriglyceridemics 
(untreated HTG, n = 24) subjects. (B) The use of fenofibrate was related to significant decreases in the expression in cir-
culating leukocytes of CX3CL1 and CCR2 genes and a significant increase in the expression of SDF-1.AIDS Research and Therapy 2009, 6:26 http://www.aidsrestherapy.com/content/6/1/26
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PCR system. Micro Fluidic Cards were analysed with RQ
documents and the RQ Manager Software for automated
data analysis. Expression values for target genes were nor-
malized to the concentration of a designated endogenous
control (GAPDH). Gene expression values were calculated
based on the comparative threshold cycle (Ct) method in
which the samples belonging to the normotriglyceridemic
group were designated as calibrators to each hypertriglyc-
eridemic group and therefore the amount of transcripts
were dimensionless numbers relative to the calibrator lev-
els via the 2-ΔΔCt method. We applied non-parametric tests
when needed and logistic regression to test the association
of gene expression with the use of fenofibrate.
Results and Discussion
There were no significant differences among the three
study groups for duration of HIV, age, body mass index
and CD4+ T cell count. Although the challenge of adher-
ence to drugs is substantial in routine HIV care, we found
a good tolerance to fenofibrate, and no complaint was
recorded. As expected, only in fenofibrate treated patients
the decrease in fasting plasma triglyceride concentration
was statistically significant as well as the increase in
plasma HDL-cholesterol levels (Figure 1A). A reduction in
plasma total cholesterol and MCP-1/CCL2 concentrations
were also observed but it did not reach statistical signifi-
cance.
With the rationale that the target for fenofibrate, PPARα,
is expressed in leukocytes [7] we explored the mRNA
expression of selected chemokine genes in whole blood.
We found that with respect to untreated patients there was
no change in the expression of chemokine receptors
CX3CR1 and CXCR4 but the expression of CCR2 was sig-
nificantly decreased in patients treated with fenofibrate
(U-Mann-Whitney, p = 0.016; Figure 1B). Of note, CCR2
gene expression was positively correlated with CD4+ T cell
count only in those patients that were undergoing fenofi-
brate treatment (Spearman, ρ = 0.7; p = 0.02). The expres-
sion of ligands for these receptors was clearly different. We
did not find any significant effect of fenofibrate in the
MCP-1/CCL2 gene expression. However, there was a sig-
nificant decrease in the gene expression of the CX3CL1/
Fractalkine in patients treated with fenofibrate with
respect to untreated hypertriglyceridemic patients (U-
Mann-Whitney, p = 0.038; Figure 1B). This is probably
accompanied by decreased CX3CL1 plasma levels and a
similar effect in the contiguous endothelial cells, which,
in combination with the CCR2 decreased expression,
could be beneficial with respect to the risk of atheroscle-
rosis considering their well documented role in the local
accumulation of monocytes [8,9]. However, fenofibrate
had an intriguing effect in SDF-1 expression neutralizing
the significant decrease in its expression observed in
untreated hypertriglyceridemics (U-Mann-Whitney, p =
0.026; Figure 1B), presumably increasing SDF-1 values.
SDF-1 plays a significant role in HIV infection because it
is the natural ligand for CXCR4 which is used by HIV T-
tropic strains to enter into the cells in advanced stages of
the disease [10]. Additionally, although the interpretation
of SDF-1 levels is difficult we have previously shown that
the allelic variant SDF1-3'A appears to be protective
against the development of carotid atherosclerosis [11].
In multivariate analysis, only fenofibrate treatment signif-
icantly contributed to explain CCR2 [B = 0.18 (0.003 to
0.09); P = 0.04] and SDF-1 [B = 4.6 (1.1 to 18.0); P = 0.03]
expression levels in hypertriglyceridemic patients. This
relationship, however, was not maintained in CX3CL1/
Fractalkine expression [B = 0.23 (0.04 to 1.1); P = 0.07].
Therefore, our results show less lipid disturbances with
the addition of fenofibrate in patients with HIV, which is
accompanied by significant changes in the pattern of
chemokine gene expression in circulating leukocytes. The
data suggest that PPARα activators may be useful in the
attempt to decrease the risk of atherosclerosis and may act
as modulators of systemic inflammation and the associ-
ated vascular response. However, further studies in other
type of populations without lipid abnormalities should
be needed to confirm the fenofibrate effect or any lipid-
lowering drug effect on systemic inflammation. Moreover,
a note of caution should be added before the indication of
these active drugs and further studies are needed to disre-
gard potential deleterious effects on the HIV infection
itself.
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